From the *Division of Pediatric Critical Care, Nemours Children’s Hospital, Orlando, Florida
†Department of Cardiology, Boston Children’s Hospital, Boston, Massachusetts
‡Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
§Extracorporeal Life Support Organization (ELSO), University of Michigan, Ann Arbor, Michigan
¶Division of Pediatric Critical Care Medicine, John R. Oishei Children’s Hospital, Buffalo, New York
∥Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.
Submitted for consideration December 2020; accepted for publication in revised form May 2021.
Disclosure: The authors have no conflicts of interest to report.
P.M.A.A.’s institution received funding from Novartis and Tenax Therapeutics, and she discloses off-label product use of ECMO. P.M.A. A. also reports grants from the National Institutes of Health (NIH) to support research activities not specific to this study (1R13HD104432-01 Pediatric ECMO Anticoagulation CollaborativE—PEACE). This study did not use external funding.
Subsets of this study were presented on February 18, 2020 at the 49th Annual Congress of the Society of Critical Care Medicine in Orlando, FL.
Correspondence: Christine K. Koshel, Division of Pediatric Critical Care, Nemours Children’s Hospital, 6535 Nemours Parkway, Orlando, FL 32827. Email: [email protected].
